VISTA antibody therapeutic / ImmuNext, Roche - LARVOL DELTA

How Do You Start a Revolution for Systems Medicine in a Health Innovation Ecosystem? Think Orthogonally and Change Assumptions. (PubMed, OMICS) - "David Bowie was a relatable example of a revolutionary and orthogonal innovator who completely and courageously broke with the past and the present and opened up new vistas in music and performing arts...Grounding systems medicine in political determinants of planetary health, to link two fields of inquiry that have remained isolated and orthogonal since the 17th century, is nothing short of a revolution and orthogonal innovation in the making. For systems medicine to be a truly revolutionary field, it ought to acknowledge that there is no single-issue health nor single-issue politics."

Journal

Identification of a Robust ARDS Mortality-associated Neutrophil Gene Signature Using Large-scale ARDS Endotracheal Aspirate scRNA-seq (ATS 2024) - "Based on our findings (Results) we then constructed a neutrophil mortality signature of 76 genes, incorporating results from CNA and topic modeling (Srivistava 2017 ICLR, Kotliar 2019 eLife) applied to the neutrophils...01 in blood). ConclusionsWe identified potential pathways for targeting dysregulated airway neutrophils in severe ARDS patients, and provided evidence supporting the use of an influenza infection model to study a neutrophil mortality signature."

Gene Signature • Late-breaking abstract • Infectious Disease • Influenza • Novel Coronavirus Disease • Respiratory Diseases

Marchiafava-Bignami Syndrome in a Diabetic Patient (ENDO 2024) - "Pérez Álvarez, C. Ramón Carbajo, G. Morís de la Tassa, J. Pascual Gómezhttps://www.elsevier.es/en-revista-neurologia-english-edition--495-articulo-marchiafava-bignami-disease-triggered-by-poorly-S2173580816300633Unless otherwise noted, all abstracts presented at ENDO must not be released to the press or the public until the date and time of presentation...The etiology of MBS is most commonly alcoholism and malnutrition; however, there are rare case reports of MBS in patients with poorly controlled diabetes who are not alcoholic or malnourished. Wide glycemic fluctuations and subsequent osmotic changes are thought to contribute to the pathophysiology of MBS in diabetic patients. Hypoglycemia can induce osmotic stress in oligodendroglial cells, leading to the structural and functional abnormalities seen in MBS."

Clinical • Anemia • Cardiovascular • Chronic Kidney Disease • CNS Disorders • Congestive Heart Failure • Critical care • Diabetes • Genetic Disorders • Heart Failure • Hematological Disorders • Hypertension • Hypoglycemia • Infectious Disease • Metabolic Disorders • Nephrology • Obesity • Oncology • Pulmonary Arterial Hypertension • Pulmonary Disease • Renal Disease • Respiratory Diseases • Solid Tumor • Type 2 Diabetes Mellitus

High-resolution myelin-water fraction and quantitative relaxation mapping using 3D ViSTa-MR fingerprinting. (PubMed, Magn Reson Med) - "In this work, we have developed a 3D ViSTa-MRF technique that enables the acquisition of whole-brain MWF, quantitative T , T , and PD maps at 1 and 0.66 mm isotropic resolution in 5 and 15 min, respectively. This advancement allows for quantitative investigations of myelination changes in the brain."

Journal

Detection of Histoplasma capsulatum and Blastomyces dermatitidis antigens in serum using a single quantitative enzyme immunoassay. (PubMed, J Clin Microbiol) - "Comparison to the MiraVista Diagnostics Blastomyces (MVB) EIA showed 100% positive (24 of 24), negative (57 of 57), and overall (81 of 81) percent agreement...Overall, this study suggests that the GBA EIA has a high level of agreement with both of the commonly used, individual Blastomyces and Histoplasma antigen EIAs. By taking advantage of the high level of cross-reactivity between Blastomyces and Histoplasma antigen EIAs, utilization of a single antigen detection assay for these fungi provides an opportunity to optimize test utilization and decrease patient cost while maintaining a high level of diagnostic accuracy."

Journal

Standard-of-Care Bortezomib Dosing in Multiple Myeloma: An International Survey of Physicians (ASH 2023) - "Neuropathy estimates were similar to published incidences (32% with once-weekly bortezomib vs 47% with twice-weekly bortezomib) from prospective data collected from the ALCYONE, GIMEMA-QW, and VISTA randomized trials (Mateos L&L 2020). Of 317 webpage visits, 205 responses were recorded (65% completion rate). Most respondents were from US academic practices (25%, n=52), US community practices (22%, n=46), or Australian academic practices (6%, n=13); however, responses were recorded from 38 countries including 22 low- or middle-income countries (LMICs: 29% of responses, n=60). Over a third of respondents (37%, n=76) practiced in community settings, and most respondents (58%, n=119) reported >20 patients with MM under their personal care."

Hematological Disorders • Hematological Malignancies • Multiple Myeloma • Oncology • Pain • Renal Disease • Transplantation

Clinical and research updates on the VISTA immune checkpoint: immuno-oncology themes and highlights. (PubMed, Front Oncol) - "Given the potential benefits of VISTA blockade in the context of cancer therapy, the second Annual VISTA Symposium was convened virtually on September 23, 2022, to review new research from investigators and immuno-oncology experts. Discussions in the meeting extended the knowledge of VISTA biology and the effects of VISTA inhibition, particularly on cells of the myeloid lineage and resting T cells, as three candidate anti-VISTA antibodies are in, or nearing, clinical development."

Immuno-oncology • Journal • Review • Oncology • PD-1

"@PMOIndia @madhuchopra @NM_ObGyn @LoksabhaB @BJP4MP @GovernorMP @IYCMadhya @BajrangDalOrg @barandbench @pfizer @Roche @airvistara @mansukhmandviya @CNNnews18 @RBArchive @ANI @MPTourism @ABVPMB @OfficialMPMetro @POTUS @bill" (@docsniks)

Structural and biochemical insights into purine-based drug molecules in hBRD2 delineate a unique binding mode opening new vistas in the design of inhibitors of the BET family. (PubMed, Acta Crystallogr D Struct Biol) - "Here, high-resolution crystal structures of the purine class of FDA-approved drugs (theophylline, doxophylline and acyclovir) and non-FDA-approved compounds (3-methyl-7-propylxanthine and theobromine) complexed with hBRD2 bromodomains BD1 and BD2 are reported. In addition, slight variations in the lipophilicity of these molecules significantly affected the in vitro binding affinity and selectivity towards BD1 compared with BD2. This idiosyncratic binding provides a new structural framework to link these sites for the development of next-generation inhibitors of the BET family."

Journal • Oncology

"En entrevista, @MilyNaveja de Donación de Milagros. Hablamos de la alerta sanitaria de @COFEPRIS por el medicamento Cellpet, de @Roche Puede afectar a pacientes transplantados #InformativoNTR 📻 @NTRGuadalajara" (@sonia_ssi)

Transplantation

Exploring the potential of combination immune checkpoint strategies in non-small cell lung cancer (NSCLC). (ASCO 2023) - "Gene expression of IC-targets including PDCD1 (PD-1), CD274 (PD-L1), CTLA4, TIGIT, LAG3, HAVCR2 (TIM-3), VSIR (VISTA), ICOS, CD276 (B7-H3), BTLA, IDO1, KLRD1 (CD94/NKG2A), NT5E (CD73), TNFRSF4 (OX-40), TNFRSF18 (GITR), and TNFRSF9 (4-1BB) were obtained... Our study identified many IC targetable genes that were significantly overexpressed in tumors. However, subsets of tumors showed distinct and segregable combinations of overexpressed IC genes. These results suggest heterogeneous mechanisms of immune evasion in NSCLC, which may explain suboptimal outcomes with anti-PD-1/PD-L1 based strategies in this patient population."

IO biomarker • Immune Modulation • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • BTLA • CD276 • CTLA4 • HAVCR2 • ICOS • IDO1 • KLRC1 • LAG3 • NT5E • TIGIT • TNFRSF4 • TNFRSF8 • TNFRSF9 • VSIR

Adapting Imaging Mass Cytometry to Explore Renal Allograft Inflammation and Develop a Tissue-Based Classifier (ATC 2023) - "We have established a novel, IMC-based approach to quantify & characterize immune subpopulations in INF and incorporating intracellular spatial features have developed a novel classifier of allograft inflammation, which demonstrates high diagnostic accuracy."

Antibody-mediated Rejection • Inflammation • Nephrology • Transplantation • CD68 • CD8 • PTPRC

"Gracias al patrocinio de @BayerEspana, @GSK_ES, @illuminaqpcr, @BoehringerES, @roche_e, @PhrmMar, @BlueprintMeds🤝 #asarga #sarcoma #sarcomacancer #sarcomawareness #oncologia #jornadas #declaraciones #entrevista" (@asargasarcoma)

Oncology • Sarcoma • Solid Tumor

"Patrocinador Platinum @mercadorevista Patrocinador Oro @Novartis Patrocinador Plata @Segurosreservas Miembros Protectores Platinum @OMG_Strategy Miembros Protectores Oro @falcondord @BancoBHD @MSCCargo #RocheCAC @Roche @DSV_AS @NestleRD @JMMBRD" (@camdomsuiza)

"Patrocinador Platinum @mercadorevista Patrocinador Oro @Novartis Patrocinador Plata @Segurosreservas Miembros Protectores Platinum @OMG_Strategy Miembros Protectores Oro @falcondord @BancoBHD @MSCCargo #RocheCAC @Roche @DSV_AS @NestleRD @JMMBRD" (@camdomsuiza)

"Patrocinador Platinum @mercadorevista Patrocinador Plata @Segurosreservas Miembros Protectores Platinum @OMG_Strategy Miembros Protectores Oro @falcondord @BancoBHD @MSCCargo #RocheCAC @Roche @DSV_AS @NestleRD @JMMBRD" (@camdomsuiza)

VISTA expression and patient selection for immune-based anticancer therapy. (PubMed, Front Immunol) - "Understanding these mechanisms is an important foundation of rational patient selection for anti-VISTA therapy. We provide a general framework to describe distinct patterns of VISTA expression in correlation with other known predictive immunotherapy biomarkers (programmed cell death ligand 1 and tumor-infiltrating lymphocytes) across solid tumors to facilitate investigation of the most efficacious TMEs for VISTA-targeted treatment as a single agent and/or in combination with anti-programmed death 1/anti-cytotoxic T lymphocyte antigen-4 therapies."

Biomarker • IO biomarker • Journal • Review • Immune Modulation • Oncology • Solid Tumor • VSIR

"Patrocinador Platinum @mercadorevista Patrocinador Oro @Novartis Patrocinador Plata @Segurosreservas Miembros Protectores Platinum @OMG_Strategy Miembros Protectores Oro @falcondord @BancoBHD @MSCCargo #RocheCAC @Roche @DSV_AS @NestleRD @JMMBRD" (@camdomsuiza)

"Patrocinador Platinum @mercadorevista Patrocinador Plata @Segurosreservas Miembros Protectores Platinum @OMG_Strategy Miembros Protectores Oro @falcondord @BancoBHD @MSCCargo #RocheCAC @Roche @DSV_AS @NestleRD @JMMBRD" (@camdomsuiza)

"Los parásitos del estado: @chevrolet @MovistarVe @ToyotaLatino @Ford @Cargill @Chrysler @AmericanAir @Nestle @ProcterGamble @Novartis @Roche @Bayer @pfizer @goodyear ups 🤭" (@BecerroFree)

Pharmacokinetic and pharmacodynamic data from a Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients with Advanced Solid Tumors (SITC 2022) - P1 | "1 Further evaluation of the immune system and PK properties of CI-8993 will be performed as we continue enrollment to determine the RP2D. Trial Registration NCT04475523"

Clinical • P1 data • PK/PD data • Oncology • Solid Tumor • CD69 • CD8 • IL18 • IL6 • TNFA

Development of a Tissue-Based Classifier of Allograft Inflammation Using Imaging Mass Cytometry (KIDNEY WEEK 2022) - "Granzyme, CD68 and Vista were the three most important markers in achieving this high accuracy. Conclusion Using highly multiplexed imaging of renal allograft biopsies with subcellular resolution by IMC we have developed a novel classifier of allograft inflammation, which demonstrates high diagnostic accuracy. Figure 1"

Immunology • Inflammation • Nephrology • CD68 • PTPRC

"Foro Reflexiones COVID-19 - Reflexiones de la pandemia por SARS-CoV-2 @DrAJRodriguezM @JECastellanos2 @MeVacuno @infopresidencia @petrogustavo @tavogamez @elcolombiano @RevistaSemana @RockefellerUniv @Roche @SaludPublicUdeA @Fundpfizer_ES https://t.co/zdayASsUEI" (@microudea)

Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

"Invitamos a leer la edición 115 de la Revista Suiza. El tema central es la Presencia de Suiza en Colombia. Gracias a @clariant @Givaudan @Hilti @Novartis @RocheColombia @Syngenta @SuizaColombia @Colegiohelvetia @FundacionSuizoColombiana. https://t.co/KcxvRFD7BU" (@colsuizacam)

"#THINKHEALTH2022 es posible gracias a nuestros aliados #RocheCAC @roche @nyphospital @revistamercado @segurosreservasrd." (@camdomsuiza)

Clinical